integrating them into proton 
therapy solutions. In 2022, IBA has recorded a value increase of 
the investment by EUR 1.0 million against the 
Groups Statement of Other Comprehensive 
Income, based on a valuation exercise using 
the DCF method and future cash flow forecasts. In July 2023, the investee has formally informed 
the stakeholder of the financial difficulties 
encountered and the start of a voluntary 
dissolution.